EUVIMEDEUVIMED entdecken
Crossref

On sample size calculation in drug interaction trials

Paul Meyvisch iD, Mitra Ebrahimpoor

Pharmaceutical Statistics · 2024-07 · 23 (4) · 530-539

DOI: 10.1002/pst.2367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 14.02.2024. Verfasst von Paul Meyvisch und 1 weiteren Autor:innen. Beteiligte Einrichtung: I-BioStat, Universiteit Hasselt, Diepenbeek, Belgium. Hauptthemen laut MEDLINE: Drug Interactions, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug–drug interaction (DDI) trials are an important part of drug development as they provide evidence on the benefits and risks when two or more drugs are taken concomitantly. Sample size calculation is typically recommended to be based on the existence of clinically justified no‐effect boundaries but these are challenging to define in practice, while the default no‐effect boundaries of 0.8–1.25 are known to be overly conservative requiring a large sample size. In addition, no‐effect boundaries are of little use when there is prior pharmacological evidence that a mild or moderate interaction between two drugs may be present, in which case effect boundaries would be more useful. We introduce precision‐based sample size calculation that accounts for both the stochastic nature of the pharmacokinetic parameters and the anticipated width of (no‐)effect boundaries, should these exist. The methodology is straightforward, requires considerably less sample size and has favorable operating characteristics. A case study on statins is presented to illustrate the ideas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsHydroxymethylglutaryl-CoA Reductase InhibitorsSample SizeHumansResearch DesignClinical Trials as TopicDrug Development

Stichwörter der Autor:innen

drug interactionprecision

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • I-BioStat, Universiteit Hasselt, Diepenbeek, Belgium.
  • Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Paul Meyvisch

Zitieren

APA

Meyvisch, P., & Ebrahimpoor, M. (2024). On sample size calculation in drug interaction trials. Pharmaceutical Statistics, 23(4), 530-539. https://doi.org/10.1002/pst.2367

Vancouver

Meyvisch P, Ebrahimpoor M. On sample size calculation in drug interaction trials. Pharmaceutical Statistics. 2024;23(4):530-539. doi:10.1002/pst.2367

BibTeX
@article{Meyvisch2024,
  author = {Meyvisch, Paul and Ebrahimpoor, Mitra},
  title = {On sample size calculation in drug interaction trials},
  journal = {Pharmaceutical Statistics},
  year = {2024},
  volume = {23},
  number = {4},
  pages = {530--539},
  doi = {10.1002/pst.2367}
}
Kostenlos starten →